Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Bet On This Biotech Before Earnings

Published 11/08/2019, 01:06 AM
Updated 03/15/2018, 09:55 AM

Biopharmaceutical name Amicus Therapeutics Inc (NASDAQ:FOLD} is expected to disclose its third-quarter earnings report before the open next Monday, Nov. 11. The stock is inching higher ahead of the event, up 1.3%, at last check. What's more, a long-term sign of technical support has just emerged, too, by way of FOLD stock's 80-month moving average.

FOLD Monthly Chart

Specifically, Amicus Therapeutics shares are within one standard deviation of their 80-month moving average, after spending a lengthy stretch north of the trendline. In fact, during the past 15 years, FOLD has made similar retreats to this trendline five other times, per data from Schaeffer's Senior Quantitative Analyst Rocky White. Three months out, FOLD was higher each time, averaging a whopping 21.35% return. At its current perch of $8.80, a similar increase would put the equity at $10.68 -- a level the stock hasn't reached since early August.

However, it should be noted that earnings history favors the bears. In the last two years, the equity has seen only one positive next-day earnings reaction, and has averaged a 5.3% post-earnings swing, regardless of direction. This time around, the options market is pricing in an even bigger next-day move of 9.8%.

Regardless, analyst sentiment has been quite optimistic, with 10 of the 11 in coverage calling Amicus a "strong buy." Plus, the consensus 12-month target price sits all the way up at $17.95, which is more than double FOLD's current levels, and represents a region not touched on the charts since 2015.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Options traders have been incredibly bullish too, with an eyebrow-raising 24.5 calls purchased for every put during the past 10 days at the the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). This ratio stands higher than 81% of all other readings from the past year, suggesting that this heavy preference for calls is unusual. However, it should be noted that FOLD's options volume runs very light on an absolute basis.

Lastly, while short interest has started to unwind, these pessimistic positions still make up 11.8% of the stock's available float. What's more, at FOLD's average pace of trading, it would take over seven days to buy back all these bearish bets, which could put some wind at the equity's back, should even more of these shorts start to jump ship.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.